Cargando…
Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes
PURPOSE AND OBJECTIVES: The objective of our study was to model the costs and benefits of 2 screening criteria for people with gestational diabetes. Because people with a history of gestational diabetes are at increased risk for type 2 diabetes, we modeled the effects of a postdelivery intervention...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809391/ https://www.ncbi.nlm.nih.gov/pubmed/36580414 http://dx.doi.org/10.5888/pcd19.220055 |
_version_ | 1784863113754968064 |
---|---|
author | Neuwahl, Simon J. Sharma, Andrea J. Zhang, Ping Hoerger, Thomas J. |
author_facet | Neuwahl, Simon J. Sharma, Andrea J. Zhang, Ping Hoerger, Thomas J. |
author_sort | Neuwahl, Simon J. |
collection | PubMed |
description | PURPOSE AND OBJECTIVES: The objective of our study was to model the costs and benefits of 2 screening criteria for people with gestational diabetes. Because people with a history of gestational diabetes are at increased risk for type 2 diabetes, we modeled the effects of a postdelivery intervention based on the Diabetes Prevention Program, which is offered to all people with a history of gestational diabetes defined by either set of criteria. INTERVENTION APPROACH: We used a probabilistic decision tree model to compare the cost-effectiveness of the International Association of Diabetes in Pregnancy Study Group’s (IADPSG’s) screening criteria and the Carpenter–Coustan screening criteria for gestational diabetes through delivery and a follow-up period during which people might develop type 2 diabetes after pregnancy. EVALUATION METHODS: The model included perinatal outcomes for the infant and mother and a 10-year postdelivery period to model maternal progression to type 2 diabetes. The model assumed the health care system perspective. People with gestational diabetes received treatment for gestational diabetes during pregnancy, and we assumed that 10% would participate in a Diabetes Prevention Program–based postdelivery intervention to reduce the risk of type 2 diabetes. We estimated the cost-effectiveness of each screening strategy in quality-adjusted life-years (QALYs) in 2022 dollars. RESULTS: At 10% participation in a Diabetes Prevention Program–based postdelivery intervention, the Carpenter–Coustan criteria were cost-effective, compared with no screening ($66,085 per QALY). The IADPSG screening criteria were slightly less cost-effective, compared with no screening ($97,878 per QALY) or Carpenter–Coustan screening criteria ($122,279 per QALY). With participation rates of 23% or higher, the IADPSG screening criteria were highly cost-effective ($48,588 per QALY), compared with Carpenter–Coustan screening criteria. IMPLICATIONS FOR PUBLIC HEALTH: Diagnosing a larger proportion of pregnant people using the IADPSG screening criteria, compared with using Carpenter–Coustan screening criteria, is not cost-effective at low levels of participation. However, with moderate levels of participation (23%) in a Diabetes Prevention Program–based postdelivery intervention, the expanded IADPSG screening criteria are cost-effective and reach up to 4 times as many people as Carpenter–Coustan screening. |
format | Online Article Text |
id | pubmed-9809391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-98093912023-01-10 Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes Neuwahl, Simon J. Sharma, Andrea J. Zhang, Ping Hoerger, Thomas J. Prev Chronic Dis Implementation Evaluation PURPOSE AND OBJECTIVES: The objective of our study was to model the costs and benefits of 2 screening criteria for people with gestational diabetes. Because people with a history of gestational diabetes are at increased risk for type 2 diabetes, we modeled the effects of a postdelivery intervention based on the Diabetes Prevention Program, which is offered to all people with a history of gestational diabetes defined by either set of criteria. INTERVENTION APPROACH: We used a probabilistic decision tree model to compare the cost-effectiveness of the International Association of Diabetes in Pregnancy Study Group’s (IADPSG’s) screening criteria and the Carpenter–Coustan screening criteria for gestational diabetes through delivery and a follow-up period during which people might develop type 2 diabetes after pregnancy. EVALUATION METHODS: The model included perinatal outcomes for the infant and mother and a 10-year postdelivery period to model maternal progression to type 2 diabetes. The model assumed the health care system perspective. People with gestational diabetes received treatment for gestational diabetes during pregnancy, and we assumed that 10% would participate in a Diabetes Prevention Program–based postdelivery intervention to reduce the risk of type 2 diabetes. We estimated the cost-effectiveness of each screening strategy in quality-adjusted life-years (QALYs) in 2022 dollars. RESULTS: At 10% participation in a Diabetes Prevention Program–based postdelivery intervention, the Carpenter–Coustan criteria were cost-effective, compared with no screening ($66,085 per QALY). The IADPSG screening criteria were slightly less cost-effective, compared with no screening ($97,878 per QALY) or Carpenter–Coustan screening criteria ($122,279 per QALY). With participation rates of 23% or higher, the IADPSG screening criteria were highly cost-effective ($48,588 per QALY), compared with Carpenter–Coustan screening criteria. IMPLICATIONS FOR PUBLIC HEALTH: Diagnosing a larger proportion of pregnant people using the IADPSG screening criteria, compared with using Carpenter–Coustan screening criteria, is not cost-effective at low levels of participation. However, with moderate levels of participation (23%) in a Diabetes Prevention Program–based postdelivery intervention, the expanded IADPSG screening criteria are cost-effective and reach up to 4 times as many people as Carpenter–Coustan screening. Centers for Disease Control and Prevention 2022-12-29 /pmc/articles/PMC9809391/ /pubmed/36580414 http://dx.doi.org/10.5888/pcd19.220055 Text en https://creativecommons.org/licenses/by/4.0/Preventing Chronic Disease is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Implementation Evaluation Neuwahl, Simon J. Sharma, Andrea J. Zhang, Ping Hoerger, Thomas J. Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes |
title | Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes |
title_full | Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes |
title_fullStr | Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes |
title_full_unstemmed | Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes |
title_short | Postdelivery Intervention to Prevent Type 2 Diabetes and the Cost-Effectiveness of Screening Criteria for Gestational Diabetes |
title_sort | postdelivery intervention to prevent type 2 diabetes and the cost-effectiveness of screening criteria for gestational diabetes |
topic | Implementation Evaluation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809391/ https://www.ncbi.nlm.nih.gov/pubmed/36580414 http://dx.doi.org/10.5888/pcd19.220055 |
work_keys_str_mv | AT neuwahlsimonj postdeliveryinterventiontopreventtype2diabetesandthecosteffectivenessofscreeningcriteriaforgestationaldiabetes AT sharmaandreaj postdeliveryinterventiontopreventtype2diabetesandthecosteffectivenessofscreeningcriteriaforgestationaldiabetes AT zhangping postdeliveryinterventiontopreventtype2diabetesandthecosteffectivenessofscreeningcriteriaforgestationaldiabetes AT hoergerthomasj postdeliveryinterventiontopreventtype2diabetesandthecosteffectivenessofscreeningcriteriaforgestationaldiabetes |